Provider Briefing: The Insulin Aspart Supply Disruption

The ongoing shortage of Insulin Aspart has become a significant clinical and logistical challenge for providers managing patients with diabetes. As of early 2026, several formulations of Insulin Aspart remain on the American Society of Health-System Pharmacists (ASHP) drug shortage list, and the situation continues to evolve.

This briefing provides a clinical overview of the shortage for endocrinologists, internists, family medicine physicians, and other prescribers — covering the current timeline, prescribing implications, alternative therapies, cost considerations, and tools to help your patients maintain access to their mealtime insulin.

Shortage Timeline

The Insulin Aspart supply disruption has unfolded in stages:

• Mid-2024: Novo Nordisk reported manufacturing delays affecting Fiasp vials and FlexTouch pens. ASHP added Insulin Aspart injection to the current shortage list.
• Late 2024: Fiasp FlexTouch pen shortage extended, with Novo Nordisk citing continued production challenges. NovoLog vials and pens experienced intermittent regional shortages.
• December 31, 2025: Novo Nordisk discontinued distribution of its unbranded biologic Insulin Aspart — the authorized generic version originally introduced to improve affordability. This removed a critical lower-cost option from the market.
• Early 2026: The shortage persists. Fiasp FlexTouch pens remain limited. NovoLog is more consistently available but subject to spot shortages depending on region and distributor. No confirmed resolution date has been announced.

Prescribing Implications

The shortage affects clinical decision-making in several key areas:

Formulary and Insurance Considerations

With the discontinuation of unbranded Insulin Aspart, patients previously on the lower-cost generic may need to transition to brand-name NovoLog or Fiasp — or switch to an alternative rapid-acting insulin entirely. This may trigger formulary issues:

• Some plans may require prior authorization for non-preferred rapid-acting insulins
• Patients switching from generic to brand may face higher copays unless covered by manufacturer savings programs
• Consider proactively checking your patient's formulary before prescribing a switch

Pump Compatibility

Patients using continuous subcutaneous insulin infusion (CSII) may be affected if their pump is configured specifically for Insulin Aspart. While most modern pumps are compatible with multiple rapid-acting analogs, verify compatibility before switching:

• Insulin Lispro (Humalog) is compatible with most insulin pumps
• Insulin Glulisine (Apidra) is approved for pump use but less commonly stocked
• Consult pump manufacturer guidelines for specific compatibility information

Dosing Considerations When Switching

Rapid-acting insulin analogs (Aspart, Lispro, Glulisine) are generally considered interchangeable on a unit-for-unit basis. However:

• Monitor patients more closely during the first 1-2 weeks of a switch
• Patients transitioning from Fiasp (faster-acting Insulin Aspart) may notice a slightly different postprandial profile when switching to standard rapid-acting analogs
• Dose adjustments may be necessary for patients with hepatic or renal impairment, where insulin clearance may be altered

Current Availability Picture

As of March 2026, the following products are affected:

• Fiasp FlexTouch (100 units/mL, 3 mL pen): Limited availability. Novo Nordisk has not provided a resolution date.
• Fiasp vials (100 units/mL, 10 mL): Intermittent availability. Manufacturing delays expected to continue.
• Fiasp PenFill cartridges: Sporadic availability depending on distributor.
• NovoLog vials and FlexPen/FlexTouch: Generally more available than Fiasp, but regional shortages occur.
• Unbranded biologic Insulin Aspart: Discontinued as of December 31, 2025. No longer available.

Providers can direct patients to Medfinder for Providers to check real-time pharmacy availability and help patients locate in-stock pharmacies.

Cost and Access Considerations

Understanding the current cost landscape helps when counseling patients:

For Commercially Insured Patients

• Novo Nordisk savings card: Eligible patients pay as little as $35/month for NovoLog or Fiasp (up to 3 vials or 2 pen packs)
• Novo Nordisk reduced the list price of NovoLog by 75% effective January 1, 2024
• Generic Insulin Aspart (where still available from other manufacturers) may offer additional savings

For Medicare Patients

• The Inflation Reduction Act caps insulin out-of-pocket costs at $35/month under Medicare Part D
• No deductible applies to covered insulin products
• For selected insulins, Medicare-negotiated prices may further reduce costs (e.g., NovoLog at ~$30/month)

For Uninsured or Underinsured Patients

• Novo Nordisk PAP (Patient Assistance Program): Provides free insulin to eligible patients. No registration fee. Apply at novocare.com
• GoodRx and discount programs: Generic Insulin Aspart as low as $74 with coupons
• Walmart ReliOn: Regular human insulin (Novolin R) available OTC for ~$25/vial as an emergency backup — not a direct substitute for rapid-acting analogs

For detailed savings information to share with patients, see How to Save Money on Insulin Aspart in 2026.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder allows providers and their staff to check real-time pharmacy availability of Insulin Aspart by zip code. This can be especially useful for:

• Helping patients find in-stock pharmacies before they leave the office
• Directing patients to specific pharmacies when writing new prescriptions
• Reducing call-backs from patients who can't find their medication

ASHP Drug Shortage Resources

The ASHP maintains an updated drug shortage database with the latest information on Insulin Aspart supply status, affected NDCs, and estimated resolution dates.

NovoCare for HCPs

Novo Nordisk's NovoCare HCP portal provides tools for patient assistance applications, savings card enrollment, and clinical support.

Alternative Agents: A Quick Reference

When Insulin Aspart is unavailable, consider these alternatives:

• Insulin Lispro (Humalog / generic): Most direct substitute. Similar pharmacokinetic profile. Available as vials, KwikPen, and cartridges. Generic version widely available.
• Insulin Glulisine (Apidra): Comparable rapid-acting profile. Less commonly used but a viable option. Available as vials and SoloStar pen.
• Admelog (Insulin Lispro biosimilar): Often more affordable. Similar efficacy to Humalog.
• Lyumjev (faster-acting Insulin Lispro): Eli Lilly's ultra-rapid formulation, similar in concept to Fiasp. Consider for patients transitioning from Fiasp specifically.

For a patient-facing comparison, share: Alternatives to Insulin Aspart.

Looking Ahead

Several developments may improve the supply situation in the coming months:

• Biosimilar approvals: Products like Kirsty and Trurapi (biosimilar Insulin Aspart) have received regulatory approvals in some markets and may expand availability
• Novo Nordisk manufacturing investments: The company has invested in expanding production capacity, though timelines remain uncertain
• Policy developments: The Inflation Reduction Act's insulin cost caps and potential future legislation could further improve affordability and access

Final Thoughts

The Insulin Aspart shortage requires proactive management from prescribers. By staying informed on supply status, knowing the alternatives, and leveraging tools like Medfinder for Providers, you can help your patients maintain uninterrupted diabetes management during this challenging period.

For patient-focused resources, direct your patients to our articles on finding Insulin Aspart in stock and the shortage update for patients.